Literature DB >> 29723617

CD14+ monocytes contribute to inflammation in chronic nonbacterial osteomyelitis (CNO) through increased NLRP3 inflammasome expression.

D Brandt1, E Sohr1, J Pablik2, A Schnabel1, F Kapplusch1, K Mäbert1, J H Girschick3, H Morbach4, F Thielemann5, S R Hofmann1, C M Hedrich6.   

Abstract

The pathophysiology of chronic nonbacterial osteomyelitis (CNO) remains incompletely understood. Increased NLRP3 inflammasome activation and IL-1β release in monocytes from CNO patients was suggested to contribute to bone inflammation. Here, we dissect immune cell infiltrates and demonstrate the involvement of monocytes across disease stages. Differences in cell density and immune cell composition may help to discriminate between BOM and CNO. However, differences are subtle and infiltrates vary in CNO. In contrast to other cells involved, monocytes are a stable element during all stages of CNO, which makes them a promising candidate in the search for "drivers" of inflammation. Furthermore, we link increased expression of inflammasome components NLRP3 and ASC in monocytes with site-specific DNA hypomethylation around the corresponding genes NLRP3 and PYCARD. Our observations deliver further evidence for the involvement of pro-inflammatory monocytes in the pathophysiology of CNO. Cellular and molecular alterations may serve as disease biomarkers and/or therapeutic targets.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29723617     DOI: 10.1016/j.clim.2018.04.011

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  9 in total

Review 1.  Chronic non-bacterial osteomyelitis and autoinflammatory bone diseases.

Authors:  Yongdong Zhao; Polly J Ferguson
Journal:  Clin Immunol       Date:  2020-05-07       Impact factor: 3.969

Review 2.  Epigenetic Regulation of Inflammatory Signaling and Inflammation-Induced Cancer.

Authors:  Shawn Ying Xuan Tan; Jieqiong Zhang; Wee-Wei Tee
Journal:  Front Cell Dev Biol       Date:  2022-06-08

3.  Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.

Authors:  A V Ramanan; L V Hampson; H Lythgoe; A P Jones; B Hardwick; H Hind; B Jacobs; D Vasileiou; I Wadsworth; N Ambrose; J Davidson; P J Ferguson; T Herlin; A Kavirayani; O G Killeen; S Compeyrot-Lacassagne; R M Laxer; M Roderick; J F Swart; C M Hedrich; M W Beresford
Journal:  PLoS One       Date:  2019-06-05       Impact factor: 3.240

Review 4.  The Role of Epigenetics in Autoimmune/Inflammatory Disease.

Authors:  Anna Elisa Andrea Surace; Christian M Hedrich
Journal:  Front Immunol       Date:  2019-07-04       Impact factor: 7.561

5.  Mast cells enhance sterile inflammation in chronic nonbacterial osteomyelitis.

Authors:  Stephanie Young; Namit Sharma; Jae Hoon Lee; Violeta Chitu; Volker Neumeister; Elisabeth Sohr; E Richard Stanley; Christian M Hedrich; Andrew W B Craig
Journal:  Dis Model Mech       Date:  2019-08-20       Impact factor: 5.758

Review 6.  Chronic nonbacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO).

Authors:  Dan Yongdong Zhao; Liza McCann; Gabriele Hahn; Christian M Hedrich
Journal:  J Transl Autoimmun       Date:  2021-03-20

Review 7.  Inflammasomes in Alveolar Bone Loss.

Authors:  Yang Li; Junqi Ling; Qianzhou Jiang
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

8.  Identification of NLRP3 Inflammation-Related Gene Promoter Hypomethylation in Diabetic Retinopathy.

Authors:  Hui Chen; Xiongze Zhang; Nanying Liao; Yuying Ji; Lan Mi; Yuhong Gan; Yongyue Su; Feng Wen
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-11-02       Impact factor: 4.799

Review 9.  Epigenetic Mechanisms of Inflammasome Regulation.

Authors:  Giulia Poli; Consuelo Fabi; Marina Maria Bellet; Claudio Costantini; Luisa Nunziangeli; Luigina Romani; Stefano Brancorsini
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.